Pricing Availability   Qty
Description: Selective vasopressin V1A antagonist
Purity: ≥95% (HPLC)
Citations (1)
Literature (1)

Biological Activity for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin is a selective vasopressin V1A receptor antagonist. Inhibits vasopressin and oxytocin-induced increases in intracellular calcium concentrations in vitro (IC50 values are 5 and 30 nM respectively). Exhibits potent and prolonged antivasopressor activity and induces anxiolytic-like effects in the dorsal, but not ventral, hippocampus in vivo.

Technical Data for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

M. Wt 1151.38
Formula C52H74N14O12S2

(Modifications: X = Pmp, Tyr-2 = Tyr(Me), Disulfide bridge: 1-6, Gly-9 = C-terminal amide)

Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 73168-24-8
PubChem ID 122173055
Smiles COC1=CC=C(C[C@@H]2NC(=O)CC3(CCCCC3)SSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC3=CC=CC=C3)NC2=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Solubility Soluble to 2 mg/ml in water

Product Datasheets for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Certificate of Analysis / Product Datasheet
Select another batch:

References for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

References are publications that support the biological activity of the product.

Kruszynski et al (1980) [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]arginine-vasopressin and [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid)]arginine-vasopressin, two highly potent antagonists of the vas J.Med.Chem. 23 364 PMID: 6892930

Spath et al (1996) Arginine vasopressin and oxyt. increase intracellular calcium and cAMP in human glomerular epithelial cells in culture. Kidney Blood Press.Res. 19 81 PMID: 8871886

Tsuchiya et al (2002) Vasopressin inhibits sarcolemmal ATP-sensitive K+ channels via V1 receptors activation in the guinea pig heart. Circ.J. 66 277 PMID: 11922278

Engin and Treit (2008) Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus. Neuropeptides 42 411 PMID: 18508119

If you know of a relevant reference for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin, please let us know.

View Related Products by Product Action

View all Vasopressin Receptor Antagonists

Keywords: (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin, (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin supplier, Selective, vasopressin, V1A, antagonists, V2, Receptors, Vasopressin, 3377, Tocris Bioscience

1 Citation for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

Citations are publications that use Tocris products. Selected citations for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin include:

Campos-Lira et al (2019) Dynamic Modulation of Mouse Locus Coeruleus Neurons by Vasopressin 1a and 1b Receptors. Front Neurosci 12 919 PMID: 30618551

Do you know of a great paper that uses (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin from Tocris? Please let us know.

Reviews for (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin

There are currently no reviews for this product. Be the first to review (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin and earn rewards!

Have you used (d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.